PUNIT DHILLON - 29 Feb 2024 Form 4 Insider Report for Skye Bioscience, Inc. (SKYE)

Signature
/s/ Kaitlyn Arsenault, as Attorney-in-Fact
Issuer symbol
SKYE
Transactions as of
29 Feb 2024
Net transactions value
$0
Form type
4
Filing time
01 Mar 2024, 18:24:43 UTC
Previous filing
06 Nov 2023
Next filing
27 Aug 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SKYE Common Stock Award $0 +100,000 +34% $0.000000 397,006 29 Feb 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SKYE Stock Option (Right to Buy) Award $0 +125,000 $0.000000 125,000 29 Feb 2024 Common Stock 125,000 $14.56 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award that vests on the following performance milestones : 25% vests upon achieving a market cap of $750M and a stock price of $20.00 per share, an additional 25% vests upon achieving a market cap of $1B and a stock price of $25.00 per share, an additional 25% vests upon achieving a market cap of $1.25B and a stock price of $30.00 per share, an additional 25% vest at if the Company is acquired for total consideration of $1.5B or greater and a stock price of $35.00 per share; provided, however, that no RSUs shall vest until the compensation committee of the Issuer determines that shares can be sold into the market to cover withholding tax obligations associated with the vesting of the RSUs. Upon a change in control of the Issuer, 100% of the options will become fully vested.
F2 Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F3 The option grant shall be exercisable for a price of $14.56 per option share for ten years from February 29, 2024 and the options will vest in equal monthly installments over the four year period beginning February 29, 2024. Upon a change in control of the Issuer, 100% of the options will become fully vested.